Published Date: 11 Nov 2024
News, features, and commentary about cancer-related issues
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
2.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
3.
'Dawson's Creek' Star Has Cancer; Radiotherapy Tattoos; Case of 'Petticoat' Cancer
4.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
5.
Advancing Health in Africa
1.
Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained
2.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
3.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
4.
Is AI The New Radiologist For Breast MRI?
5.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation